1. Home
  2. MTA vs ANNX Comparison

MTA vs ANNX Comparison

Compare MTA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

SELL

Current Price

$7.79

Market Cap

902.2M

Sector

N/A

ML Signal

SELL

Logo Annexon Inc.

ANNX

Annexon Inc.

SELL

Current Price

$3.68

Market Cap

726.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MTA
ANNX
Founded
1983
2011
Country
Canada
United States
Employees
N/A
92
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
902.2M
726.1M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
MTA
ANNX
Price
$7.79
$3.68
Analyst Decision
Buy
Buy
Analyst Count
2
10
Target Price
$9.16
★ $15.43
AVG Volume (30 Days)
286.9K
★ 3.0M
Earning Date
08-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$68.62
N/A
Revenue Next Year
$67.46
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$2.54
52 Week High
$11.60
$7.18

Technical Indicators

Market Signals
Indicator
MTA
ANNX
Relative Strength Index (RSI) 27.13 33.33
Support Level $6.34 N/A
Resistance Level $7.97 $4.37
Average True Range (ATR) 0.31 0.21
MACD -0.17 0.01
Stochastic Oscillator 3.54 7.33

Price Performance

Historical Comparison
MTA
ANNX

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal and copper royalties and streams. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: